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Abstract  
Background: Long-term complications of diabetes include cardiovascular disease, 
retinopathy, nephropathy, and neuropathy. Diabetic patients with prostate cancer could be at a 
high risk of radiation-induced acute proctitis following radical radiotherapy. Our aims were to 
analyse the incidence, severity, and duration of radiation proctitis in diabetic patients treated 
by radical radiotherapy and combined androgen deprivation for prostate cancer. 
Material and Methods: On the bases of inclusion and exclusion criteria 716 patients with 
prostate cancer were retrospectively recruited. Patients were stratified into diabetic patients and 
non-diabetic patients. The incidence, severity, and duration of proctitis were the main 
outcomes. A polynomial ordered logistic regression was fitted to determine the influence of 
diabetes status, age, blood pressures medication, co-morbidities, Gleason score, PSA after 
treatment, and tumour stage on the grades of proctitis. Time to resolution per year was modelled 
as a negative binomial generalised linear model.  
Results: The overall mean age of patients was 67.44 (SD 6.77) years with a follow-up time of 
3.36 (SD 2.05) years. Data exploratory analysis suggested that the only highly significant 
explanatory variable was the presence or absence of diabetes. Polynomial ordered logistic 
regression, however, showed that the presence (or not) of diabetes remained as the only 
significant predictor (t = -2.74; p = 0.0059) of severity of proctitis. A negative binomial 
generalised linear model showed that both grade of proctitis (z = -17.178; p < 0.001), and 
diabetes (z = -5.92; p < 0.001), were highly significant predictors of time to resolution.  
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Conclusions: Diabetic patients were significantly more likely to have proctitis after radical 
radiation therapy for prostate cancer. Diabetes was significantly associated with an induced 
risk of radiation induced proctitis and also with deceleration of its resolution. 
Keywords: Prostate cancer; Diabetes mellitus; Proctitis; Radiotherapy.  
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Introduction 
Diabetes mellitus is the one of the most common endocrine diseases in Britain. Long-standing 
uncontrolled diabetes could lead to long-term complications, including cardiovascular disease, 
retinopathy, nephropathy, and neuropathy (, 1). 
A series of studies (2 - 5) have investigated the impact of diabetes mellitus on radiation toxicity 
of several organs such as lung and prostate. In lung cancer diabetic patients are at risk to 
develop clinically symptomatic pneumonitis following radiation therapy (2 - 4), with no 
significant difference between patients who had long or short-term diabetic history (4). 
Recently, Zhou et al. (5) reported a significant difference in the incidence of radiation 
pneumonitis between diabetic and non-diabetic patients. In prostate cancer patients, a 
multivariate analysis identified  that diabetes mellitus has a negative influence on urine 
incontinence and sexual function (6). One study (7) reported that high grade genitourinary 
toxicity was highly associated with the presence of diabetes mellitus in patients undergoing 
treatment of prostate cancer. Late gastrointestinal and urinary toxicities were significantly 
associated with diabetic patients with localized prostate cancer (8). 
Despite radical radiotherapy having become a major option in the treatment of localised or 
locally advanced prostate cancer (9), for anatomical reasons in which the rectum is adjacent to 
the prostate, radiation induced injury to the rectum is still a frequent side effect of prostate 
cancer radiotherapy (10 -14).  
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The incidence of proctitis varies; several studies (15 - 17) reported that the incidence of proctitis 
after 3D-conformal external beam radiotherapy of localized prostate cancer constitutes 
between 5 - 20%. Goldner et al. (15) reported, without using any scoring system for proctitis, 
that 10 – 20% of patients developed rectal bleeding and proctitis. Whereas Muren et al. (16) 
stated that any symptoms which require medical managements were scored at least grade 2 
toxicity; in which 17% of patients developed acute grade 2 toxicity. While others (18 - 22) 
reported that 50 - 85% of participants experience signs of proctitis include rectal discomfort, 
diarrhoea, urgency and rectal bleeding after pelvic radiation therapy. According to Potosky et 
al. (23) long period complications can comprise rectal bleeding, fistulas, stool incontinence and 
rectal discomfort with seldom patients required colostomy that results in significant decrements 
in quality of life.  
Therefore, we aimed to investigate whether diabetic patients treated by neoadjuvant/adjuvant 
hormone therapy and radical radiation therapy for prostate cancer have higher incidence, 
severity and duration of radiation proctitis. 
Material and Methods 
This retrospective study had Caldecott Institutional Approval (Caldicott/CSAppGN021211). 
716 patients underwent radical radiotherapy and neoadjuvant/adjuvant hormonal therapy were 
identified from comprehensive clinical databases hosted at one of main cancer centres in the 
United Kingdom (UK) from January 2007 to December 2013. Patients were identified from 
electronic databases through a validated cross linkage methodology as described previously in 
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detail (24, 25). Record linkage technique brings together two or more records relating to the 
same individual identified by a common identifier (Community Health Index [CHI] number in 
this series). Cross-linked databases enabled demographical and clinical data to be securely 
managed at one centralised database for the purpose of this study.   
The database with (CHI) was linked to the following clinical systems: (i) WISDOM oncology 
system (Web Information System for Data Oncology Management) which securely stores the 
following clinical information includes clinical presentation, PSA, cancer stage, Gleason score, 
radiotherapy, chemotherapy, clinical complications, follow-up and mortality; (ii) Referral 
Management System (RMS) which is a primary care system for a population of more than 
400,000 individuals. Data linkage captured the doses, start date and name of any prescribed 
medication (38, 39); (iii) Multidisciplinary Board Meeting (MDT) records where all patients 
diagnosed with prostate cancer are discussed on a weekly basis; (iv) Integrated Clinical 
Environment (ICE) system enhances clinicians with diagnostic services as a means to 
electronically order tests and view results. Using the CHI number we searched for sequential 
PSA results; (v) Records were searched using Clinical Portal and the In House Surgical 
Information System web and Technology (Insite), these databases host secure electronic patient 
records which systematically captures follow-up history including communication between 
acute and primary care.  
Inclusion criteria were: (i) patients who are newly diagnosed and histologically confirmed to 
have localized or locally advanced adenocarcinoma of prostate; (ii) patients who acquired 
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primary radical radiotherapy and neoadjuvant/adjuvant hormonal therapy; (iii) patients who 
received a dose of radiotherapy ranged between 4500cGY – 5700cGY in 20 fraction over 20 
to 32 days; and (iv) patients acquired 3D field conformal radiotherapy. Exclusion criteria were: 
(i) patients who received adjuvant radiotherapy following radical prostatectomy; (ii) patients 
with missing data including lack of the dose of radiotherapy, tumour stage, Gleason score, 
PSA, no history of follow-up or missing co-morbidity data (such as hypertension 
dyslipidaemia, cardiovascular diseases etc.); (iii) patients who had radiotherapy only; (iv) 
chronic proctitis; and (v) haemorrhoids. 
The incidence, severity and duration of radiation induced proctitis were the primary study 
outcomes. Radiation induced proctitis was graded according the European Organization for 
Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group 
(RTOG) grading system of radiation proctitis in which grade 0 has no signs and symptoms and 
does not require medication; grade 1 has minimal side effect such as urgency, occasional pain, 
superficial ulceration < 1cm2, mild stricture with occult rectal bleeding: treated as outpatient 
and does not require lifestyle adjustments; grade 2 has intermittent urgency and pain, 
superficial ulceration >1cm2, intermittent rectal bleeding and moderate stricture: treated as 
outpatient and requires lifestyle adjustments; grade 3 has persistent urgency, pain and bleeding, 
deep ulceration associated with sever stricture: needs  hospital admission or minor surgical 
intervention associated radical adjustment of the lifestyle; grade 4 has severe urgency 
associated with severe uncontrollable pain, sever bleeding, perforation, fistula and complete 
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obstruction: needs hospital admission or major surgical intervention; and grade 5 has  multi-
organ failure, sepsis and death (26, 27).  
The records were assessed for grading classification by two members of the research team (AA 
and CP) to rate the severity of proctitis for each patient (n=30) within the study. Inter-rater 
reliability between the observers was assessed using the Kappa statistic (Kappa=0.809 with 
p<0.001) and was found to have substantial agreement (28).  
Patients were stratified into 2 groups, diabetic patients (group 1) and non-diabetic patients 
(group 2) which was identified from the same centralised database. Following exploratory 
analysis with simple linear models, a polynomial ordered logistic regression was fitted to 
determine the influence of diabetes status, age, blood pressures medication, co-morbidities, 
Gleason score, PSA after treatment, and tumour stage on the grades of proctitis (scored on a 0 
– 5 ordinal scale). The time to resolution per year was modelled as a negative binomial 
generalised linear model to correct for overdispersion, with both proctitis and diabetes coded 
simply as present or absent.  
The unresolved proctitis was defined as any patient with remaining signs and symptoms of 
proctitis through the whole follow-up. The probability of any individual case remaining 
unresolved at the end of the study was modelled as a Kaplan-Meier survival object, which was 
then included as the response variable in a Cox regression model, where cases remaining 
unresolved at the end of the study period were treated as censors.  Constancy of variance in 
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model residuals and the normality of errors were checked for all analyses, which were 
conducted in R (version 3.2.2, R Core Development Team 2015). 
The two groups were treated in the same cancer centre with: (1) neoadjuvant or adjuvant 
androgen deprivation with luteinizing hormone-related hormone analogues. In neoadjuvant / 
adjuvant hormonal therapy treatment begun 3 months before radical radiotherapy and was 
administered for a total of 6, to 24 ; (2) three field conformal radiotherapy with a median dose 
of 5400cGY (ranged, 4500cGY – 5700cGY), 20 fraction (ranged, 19 – 22) and 28 days (ranged, 
20 – 32) following UK guidelines (UK guidelines, 29).  
Results 
The clinical and demographic characteristics of the study participants are shown in Table 1. 
The total number of patients who underwent 3D radical radiotherapy with neoadjuvant or 
adjuvant hormone therapy was 1046. On the bases of inclusion and exclusion criteria, 716 
patients were in included in this retrospective study.  
The overall mean age of patients was 67.44 (standard deviation [SD] 6.77) years with a follow-
up time of 3.36 (SD 2.05) years. Of 716 patients, 100 were type II diabetic and 616 non-diabetic 
patients. Exploratory analysis of the data suggested that the only clearly significant explanatory 
variable was the presence or absence of diabetes, with a marginally significant effect of blood 
pressure medication. Polynomial ordered logistic regression, however, showed that blood 
pressure medication had no significant effect (t = -0.9001; p = 0.367), and the presence (or not) 
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of diabetes remained as the only significant predictor (t = -2.74; p = 0.0059).  A negative 
binomial generalised linear model also indicated that diabetes (z = -5.92; p < 0.001), was the 
only significant predictor of time to resolution.  Model checking showed that constancy of 
model residuals across fitted values, and normality of errors were both satisfactory.  
Cox regression of the derived Kaplan-Meier object on time to resolution, showed that only 
diabetic status (present or absent) was a significant predictor of time to resolution (Figure 1), 
and that from the beginning of the second year of observation to the end of the study, there 
were significant and increasing differences between diabetic and non-diabetic patients in the 
likelihood that their acute proctitis had been resolved.  The data for diabetic and non-diabetic 
patients yielded an overall risk ratio of 2.02, indicating that diabetic patients were just over 
twice as likely, on average, to have unresolved acute proctitis.  
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Discussion 
In the present study, we evaluated the influence of diabetes mellitus on the incidence, severity, 
and duration of rectal toxicity in patients with prostate cancer who underwent radical 
radiotherapy and neoadjuvant/adjuvant hormonal therapy. Our results identified that patients 
with diabetes mellitus had significantly greater rate of high grades of proctitis (p<0.001). 
Patients without diabetes mellitus did not have an increased rate of high grades of proctitis. 
These findings might not be surprising, given several studies have indicated that diabetes 
mellitus induces radiation induced toxicity pneumonitis (2 - 5). 
A series of explanations have been theorized for this association. After surgery, there has been 
evidence suggesting that diabetes mellitus increases morbidity and mortality rates in cancer 
patients (30), which could be as a consequence of reduced leukocyte activities, including 
chemotaxins, phagocytosis and opsonization; therefore, it affects the body innate immunity 
(31). Vascularity of the organ can play a major role in its tissue repair after radiotherapy: during 
radiation, tissue damage occurs more prominently in fast proliferating cells such as the lining 
epithelium of the skin and gastrointestinal tract, the blood vessels become exposed and the 
coagulation system also become activated leading to decrease the blood flow, thrombosis and 
capillary necrosis (31 - 33). In diabetic patients, the endothelial lining of the blood vessels 
become dysfunctional and the microvasculature impaired to dilate (31); therefore, it is expected 
that diabetic patients are predicted to have impairment tissue repair after radiotherapy.  
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Few studies (2 - 5) have investigated the impact of the pre-existing diabetes mellitus on 
radiation to toxicity. In lung cancer patients with pre-existing diabetic mellitus are at risk to 
develop clinically symptomatic pneumonitis following radiation therapy (2 - 4), but 
interestingly no significant difference was observed with duration of diabetic diagnosis and 
pneumonitis (4). In prostate cancer patients, a multivariate analysis identified that diabetes 
mellitus has a negative influence on urinary incontinence and sexual function (6). In keeping 
with our findings, (8) reported that late gastrointestinal and urinary toxicities were significantly 
associated with diabetic patients with localized prostate cancer treated by 3D conformal 
radiotherapy. Our analysis of data revealed that diabetes mellitus was significantly associated 
with radiation induced proctitis when compared to patients who were not diabetic. There also 
were significant and increasing differences between diabetic and non-diabetic patients in the 
likelihood that their proctitis had been resolved.  The data for diabetic and non-diabetic patients 
yielded an overall risk ratio of 2.02, indicating that diabetic patients were just over twice as 
likely, on average, to have unresolved proctitis. 
Time to onset of late grade 2 gastrointestinal complications was not significantly different 
between diabetic and non-diabetic patients, but however time to onset of genitourinary 
complications was statistically significant (p=0.02) between diabetic and non-diabetic patients 
(34). Our findings demonstrate that Cox regression of the derived Kaplan-Meier object on time 
to resolution, showed that only diabetic status (present or absent) was a significant predictor of 
time to resolution. These findings suggest that the existence of diabetes mellitus induce the 
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onset of proctitis and deaccelerate its resolution.  However, other factors also might have 
influenced rradiation proctitis such technique, including intensity-modulated radiation therapy 
(IMRT), and varying doses.   However to the best of our knowledge, treatment of late rectal 
complication after IMRT has not been reported systematically and remains to be addressed in 
future research. 
 It could be questioned why this study has included the use of angiotensin converting enzyme 
inhibitors as a covariant factor. Our previous study (35) reported that men who were 
hypertensive and on angiotensin converting enzyme inhibitors and underwent radical 
radiotherapy for prostate cancer were significantly less likely to have radiation induced 
proctitis. Although the mechanism of angiotensin converting enzyme inhibitors to reduce the 
incidence and risk of proctitis, further work is needed fully understand the hypothesised 
pathways in which these factors might affect radiation induced proctitis. 
All of our patients in our series has type 2 diabetes, and therefore, we were unable to explore 
whether there was any significant difference in the incidence of gastrointestinal and 
genitourinary radiotoxicity between patients taking insulin and patients who were taking 
antidiabetic drugs. Elsewhere however, Kalakota (7) reported that there was no difference in 
the incidence of gastrointestinal and genitourinary tracts toxicity between patients on insulin 
verse oral medications.  Moreover, our study did not explore the influence of anticoagulant 
medication on the incidence of gastrointestinal and genitourinary tracts toxicity and this will 
remained to be explored in future studies.  
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The current study has shown that only diabetic status was a significant predictor of time to 
resolution, and that from the beginning of the second year of observation to the end of the 
study, there were significant and increasing differences between diabetic and non-diabetic 
patients in the likelihood that their acute proctitis had been resolved.   
To date, there is no evidence which has demonstrated an association between proctitis and age, 
Gleason score or stage (35); and our findings reported similar data. 
One of the limitations in the existing literature was the absence of the implementation of a 
reliable and valid method to evaluate and measure proctitis (15 - 17, 22, 36, 37). A series of 
studies has reported proctitis as present or absent without acknowledging its grades of severity 
(15 - 17). The current study has used a valid and reliable method, the EORTC and RTOG 
grading system to evaluate the severity of radiation induced proctitis (26, 27). This grading 
classification of proctitis was verified by many studies and was found to be reliable and 
consistent (38 - 41).  
All our patients were treated by three field conformal radiotherapy with a median dose of 
5400cGY (ranged, 4500cGY – 5700cGY), 20 fraction (ranged, 19 – 22) and 28 days (ranged, 
20 – 32) following UK guidelines (UK guidelines, 29); therefore, it was impossible to evaluate 
the incidence of radiation proctitis in diabetic patients who were treated by higher or lower 
doses of radiation radiotherapy as this was the UK recommended dose at that time     
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One of the limitations of this study was a short follow-up. Further study is recommended to 
evaluate the incidence, severity, and duration of radiation proctitis in diabetic patients treated 
by radical radiotherapy and combined androgen deprivation for prostate cancer with longer 
follow-up.  
Conclusion 
Our results demonstrate that diabetic patients are more likely to have high grades of proctitis 
after radical radiotherapy with neoadjuvant or adjuvant hormone therapy. Diabetic patients 
were significantly associated with induced risk of radiation induced proctitis and also with 
deceleration in its resolution. Special care and risk stratification of patients with DM under-
going RT for prostate cancer should be taken into consideration in clinical management of this 
patient group. 
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